Betical order): AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Esteve, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Novartis, and Rovi. The rest on the authors declare no conflict of interest.
biomedicinesArticleA New Light on Possible Therapeutic Targets for Colorectal Cancer TreatmentWei-Lun Tsai 1, , Chih-Yang Wang 2,3, , Yu-Cheng Lee four , Wan-Chun Tang two,3 , Gangga Anuraga 1,three,5 , Hoang Dang Khoa Ta 1,three , Yung-Fu Wu 6 and Kuen-Haur Lee two,three,7, Citation: Tsai, W.-L.; Wang, C.-Y.; Lee, Y.-C.; Tang, W.-C.; Anuraga, G.; Ta, H.D.K.; Wu, Y.-F.; Lee, K.-H. A brand new Light on Possible Therapeutic Targets for Colorectal Cancer Therapy. Biomedicines 2021, 9, 1438. https://doi.org/10.3390/ biomedicines9101438 Academic PF-07321332 custom synthesis Editors: Antonio Biondi and Marco Vacante Received: 11 August 2021 Accepted: 29 September 2021 Published: ten OctoberPhD System for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technologies, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan; [email protected] (W.-L.T.); [email protected] (G.A.); [email protected] (H.D.K.T.) PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Healthcare University, Taipei 11031, Taiwan; [email protected] (C.-Y.W.); [email protected] (W.-C.T.) Graduate Institute of Cancer Biology and Drug Discovery, College of Healthcare Science and Technology, Taipei Medical University, Taipei 11031, Taiwan Graduate Institute of Medical Sciences, College of Medicine, Taipei PD1-PDL1-IN 1 web Health-related University, Taipei 11031, Taiwan; [email protected] Department of Statistics, Faculty of Science and Technologies, Universitas PGRI Adi Buana, Surabaya 60234, East Java, Indonesia National Defense Medical Center, Division of Health-related Study, School of Medicine, Tri-Service General Hospital, Taipei 11490, Taiwan; [email protected] Cancer Center, Wan Fang Hospital, Taipei Health-related University, Taipei 11031, Taiwan Correspondence: Correspondence: [email protected] These authors contributed equally to this operate.Abstract: The improvement and progression of colorectal cancer (CRC) involve alterations in genetic and epigenetic levels of oncogenes and/or tumor suppressors. In spite of advances in understanding of your molecular mechanisms involved in CRC, the general survival rate of CRC nonetheless remains relatively low. Hence, a lot more analysis is necessary to find out and investigate productive biomarkers and targets for diagnosing and treating CRC. The roles of long non-coding RNAs (lncRNAs) participating in several aspects of cell biology have been investigated and potentially contribute to tumor improvement. Our current study also showed that CRNDE was among the major 20 upregulated genes in CRC clinical tissues in comparison with normal colorectal tissues by analyzing a Gene Expression Omnibus (GEO) dataset (GSE21815). Even though CRNDE is broadly reported to become connected with distinct sorts of cancer, most studies of CRNDE had been restricted to examining regulation of its transcription levels, and in-depth mechanistic study is lacking. Inside the present study, CRNDE was identified to become significantly upregulated in CRC sufferers at an sophisticated TNM stage, and its higher expression was correlated with poor outcomes of CRC patients. In addition, we discovered that knocking down CRNDE could cut down lipid accumulation via the miR-29b-3p/ANGPTL4 axis and consequently induce autophagy of CRC cells. Keywords and phrases: colorectal cancer; CRNDE; MiR-29b-3p; ANGPTL4; auto.